Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …

Importance Although tumor mutation burden (TMB) has been explored as a potential
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

The FDA approved pembrolizumab on June 16, 2020, for the treatment of adult and pediatric
patients with unresectable or metastatic tumor mutational burden–high [TMB-H;≥ 10 …

Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …

FoundationOne® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-
approved companion diagnostic test to identify patients who may benefit from treatment in …